Wellfully (ASX:WFLOA) EV-to-FCF: 0.00 (As of Jul. 06, 2026)


What is Wellfully EV-to-FCF?

Wellfully ASX:WFLOA EV-to-FCF is 0.00 as of Jul. 06, 2026. The stock has 7 warning signs investors should review.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Wellfully's Enterprise Value is A$0.00 Mil. Wellfully's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.06 Mil. Therefore, Wellfully's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Wellfully's EV-to-FCF or its related term are showing as below:

ASX:WFLOA' s EV-to-FCF Range Over the Past 10 Years
Min: -74.51   Med: -13.25   Max: -0.17
Current: -29.38

During the past 13 years, the highest EV-to-FCF of Wellfully was -0.17. The lowest was -74.51. And the median was -13.25.

ASX:WFLOA's EV-to-FCF is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 22.975 vs ASX:WFLOA: -29.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-06), Wellfully's stock price is A$0.00. Wellfully's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.000. Therefore, Wellfully's PE Ratio (TTM) for today is N/A.


Wellfully  (ASX:WFLOA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Wellfully's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Wellfully's share price for today is A$0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Wellfully's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Wellfully EV-to-FCF Related Terms


Wellfully EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Wellfully's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wellfully EV-to-FCF Chart

Wellfully Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.11 -10.30 -1.52 -1.72 -0.60

Wellfully Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.72 0.00 -0.60 0.00

ASX:WFLOA vs TMO, DHR, IDXX: EV-to-FCF Comparison

For the Diagnostics & Research subindustry, Wellfully's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wellfully EV-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wellfully's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Wellfully's EV-to-FCF falls into.



Wellfully EV-to-FCF Calculation

Wellfully's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-0.055
=0.00

Wellfully's current Enterprise Value is A$0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Wellfully's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of 0.00 mean?
Wellfully (ASX:WFLOA) has a EV-to-FCF of 0.00 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wellfully and its competitors.
Is Wellfully's EV-to-FCF too high?
Wellfully's current EV-to-FCF is 0.00.
How does Wellfully's EV-to-FCF compare to TMO and DHR?
Wellfully's EV-to-FCF of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EV-to-FCF is 22.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.98, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wellfully and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wellfully's current EV-to-FCF is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wellfully stock overvalued right now?
Wellfully (ASX:WFLOA) has a current EV-to-FCF of 0.00. The current EV-to-FCF is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Wellfully (ASX:WFLOA), the current EV-to-FCF is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wellfully Business Description

Address 284 Oxford Street, Ground Floor, Leederville, WA, AUS, 6007
Wellfully Ltd is engaged in the research and development of Dermaportation and ETP transdermal drug delivery technologies. The company operates in segments namely the development of the dermaportation drug delivery technology and Devices segments. Geographically, it derives a majority of its revenue from Europe and also has a presence in Japan. It serves the Pharmaceutical; Cosmetics Skincare and Consumer Healthcare industries.